BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25769964)

  • 1. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.
    Morad SA; Tan SF; Feith DJ; Kester M; Claxton DF; Loughran TP; Barth BM; Fox TE; Cabot MC
    Biochim Biophys Acta; 2015 Jul; 1851(7):919-28. PubMed ID: 25769964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.
    Morad SA; Cabot MC
    Biochim Biophys Acta; 2015 Sep; 1851(9):1134-45. PubMed ID: 25964209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.
    Morad SA; Levin JC; Tan SF; Fox TE; Feith DJ; Cabot MC
    Biochim Biophys Acta; 2013 Dec; 1831(12):1657-64. PubMed ID: 23939396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.
    Morad SA; Davis TS; Kester M; Loughran TP; Cabot MC
    Leuk Res; 2015 Oct; 39(10):1071-8. PubMed ID: 26220867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.
    Morad SAF; Davis TS; MacDougall MR; Tan SF; Feith DJ; Desai DH; Amin SG; Kester M; Loughran TP; Cabot MC
    Biochem Pharmacol; 2017 Apr; 130():21-33. PubMed ID: 28189725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo.
    Yang L; Weng W; Sun ZX; Fu XJ; Ma J; Zhuang WF
    Biochem Biophys Res Commun; 2015 May; 460(4):903-8. PubMed ID: 25824043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.
    Morad SA; Ryan TE; Neufer PD; Zeczycki TN; Davis TS; MacDougall MR; Fox TE; Tan SF; Feith DJ; Loughran TP; Kester M; Claxton DF; Barth BM; Deering TG; Cabot MC
    J Lipid Res; 2016 Jul; 57(7):1231-42. PubMed ID: 27140664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of bioactive sphingolipids in 4-HPR-resistant leukemia cells.
    Apraiz A; Idkowiak-Baldys JK; Boyano MD; Pérez-Yarza G; Hannun YA; Asumendi A
    BMC Cancer; 2011 Nov; 11():477. PubMed ID: 22061047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.
    Morad SAF; MacDougall MR; Abdelmageed N; Kao LP; Feith DJ; Tan SF; Kester M; Loughran TP; Wang HG; Cabot MC
    Exp Cell Res; 2019 Aug; 381(2):256-264. PubMed ID: 31112736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceramide Analogue SACLAC Modulates Sphingolipid Levels and
    Pearson JM; Tan SF; Sharma A; Annageldiyev C; Fox TE; Abad JL; Fabrias G; Desai D; Amin S; Wang HG; Cabot MC; Claxton DF; Kester M; Feith DJ; Loughran TP
    Mol Cancer Res; 2020 Mar; 18(3):352-363. PubMed ID: 31744877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.
    Kao LP; Morad SAF; Davis TS; MacDougall MR; Kassai M; Abdelmageed N; Fox TE; Kester M; Loughran TP; Abad JL; Fabrias G; Tan SF; Feith DJ; Claxton DF; Spiegel S; Fisher-Wellman KH; Cabot MC
    J Lipid Res; 2019 Sep; 60(9):1590-1602. PubMed ID: 31363040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.
    Maurer BJ; Melton L; Billups C; Cabot MC; Reynolds CP
    J Natl Cancer Inst; 2000 Dec; 92(23):1897-909. PubMed ID: 11106681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction.
    Hadas Y; Vincek AS; Youssef E; Żak MM; Chepurko E; Sultana N; Sharkar MTK; Guo N; Komargodski R; Kurian AA; Kaur K; Magadum A; Fargnoli A; Katz MG; Hossain N; Kenigsberg E; Dubois NC; Schadt E; Hajjar R; Eliyahu E; Zangi L
    Circulation; 2020 Mar; 141(11):916-930. PubMed ID: 31992066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acid ceramidase is upregulated in AML and represents a novel therapeutic target.
    Tan SF; Liu X; Fox TE; Barth BM; Sharma A; Turner SD; Awwad A; Dewey A; Doi K; Spitzer B; Shah MV; Morad SA; Desai D; Amin S; Zhu J; Liao J; Yun J; Kester M; Claxton DF; Wang HG; Cabot MC; Schuchman EH; Levine RL; Feith DJ; Loughran TP
    Oncotarget; 2016 Dec; 7(50):83208-83222. PubMed ID: 27825124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function.
    Ghazaly EA; Miraki-Moud F; Smith P; Gnanaranjan C; Koniali L; Oke A; Saied MH; Petty R; Matthews J; Stronge R; Joel SP; Young BD; Gribben J; Taussig DC
    J Biol Chem; 2020 Apr; 295(16):5496-5508. PubMed ID: 32161116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
    Xu L; Zhang Y; Gao M; Wang G; Fu Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of sphingolipid metabolism augments ceramide-induced autophagy in preeclampsia.
    Melland-Smith M; Ermini L; Chauvin S; Craig-Barnes H; Tagliaferro A; Todros T; Post M; Caniggia I
    Autophagy; 2015 Apr; 11(4):653-69. PubMed ID: 25853898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1.
    Bonhoure E; Pchejetski D; Aouali N; Morjani H; Levade T; Kohama T; Cuvillier O
    Leukemia; 2006 Jan; 20(1):95-102. PubMed ID: 16281067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes.
    Gencer EB; Ural AU; Avcu F; Baran Y
    Ann Hematol; 2011 Nov; 90(11):1265-75. PubMed ID: 21455605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells.
    Cakir Z; Saydam G; Sahin F; Baran Y
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):279-86. PubMed ID: 20401667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.